🇺🇸 FDA
Company

Context

Context Therapeutics

CNTX pharma USA

Quick answer

Context is a pharma company (CNTX) headquartered in PHILADELPHIA, PA, USA with 8 tracked pipeline programs.

Pipeline (8)

project

Elacestrant

Breast Cancer

Phase 2 · small_molecule · terminated

2 trials project

Extended-release Onapristone

Refractory Endometrial Adenocarcinoma

Phase 2 · small_molecule · active

1 trials project

Onapristone

ER-positive Breast Cancer

Phase 2 · small_molecule · terminated

1 trials project

Onapristone ER

Granulosa Cell Ovarian Cancer

Phase 2 · small_molecule · completed

1 trials project

CT-202

Triple Negative Breast Cancer (TNBC)

Phase 1 · small_molecule · active

1 trials project

CT-95

Mesothelin-Expressing Tumors

Phase 1 · small_molecule · active

1 trials project

CTIM-76

Platinum-resistant Ovarian Cancer

Phase 1 · small_molecule · active

1 trials project

Letrozole

Metastatic Breast Cancer

Phase 1 · small_molecule · terminated

1 trials

Patents (3)

patent

US 11672762

Onapristone extended-release compositions and methods

Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10786461

Onapristone extended-release compositions and methods

Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10548905

Amorphous onapristone compositions and methods of making the same

Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)